To begin to meet this need, we analyzed unique data from a large (>1,200) consecutive breast cancer case series from a public setting in South Africa where receptor status, including HER2, was routinely measured at diagnosis on prechemotherapy biopsy specimens. The gene discussed is ERBB2; the disease is breast cancer.